Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Zealand Pharma A/S manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. These actions are distributed across 7 distinct examiners, meaning each pending matter is under the review of a different official. Despite the number of examiners, the actions are concentrated within 2 distinct art units, suggesting that the company's pharmaceutical innovations are focused on specific technical classifications. This concentration in 2 distinct art units allows for a more focused approach to prior art analysis across the portfolio.
REYNOLDS, FRED H is identified as the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. Because the 7 distinct examiners are each handling a portion of the workload, the prosecution is distributed across the pool. This number of examiners and the limited number of art units requires a coordinated prosecution strategy to ensure consistency across applications while navigating the different perspectives of separate officials. Practitioners should be aware that the distribution across many examiners may lead to varying timelines for the pending matters. The focus on the biotechnology field remains the primary driver of the company's current patent office interactions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (80%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039992 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | FISCHER, JOSEPH | 4d overdue |
| 17279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | BEANE, RANDALL L | 29d |
| 18688026 | DOSAGE REGIME | COFFA, SERGIO | — |
| 18275195 | COMPOSITION FOR TREATING SHORT BOWEL SYNDROME | NIEBAUER, RONALD T | — |
| 18037795 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 4 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688026 | DOSAGE REGIME | COFFA, SERGIO | 1658 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18275195 | COMPOSITION FOR TREATING SHORT BOWEL SYNDROME | NIEBAUER, RONALD T | 1658 | §103Other | Final Rejection | — | Pending | Jul 31, 2023 |
| 18039992 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | FISCHER, JOSEPH | 1658 | §103Other | Final Rejection | 4d overdue | Pending | Jun 02, 2023 |
| 18037795 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Final Rejection | — | Pending | May 19, 2023 |
| 17279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 29d | Pending | Mar 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZealand Pharma A/S has 5 pending office actions as of October 2026, spread across 2 art units and 5 examiners.
Sergio Coffa has the most, with 1 of Zealand Pharma A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
